<p>Neurocrine Biosciences, Inc.（納斯達克股票代碼：NBIX）內部人員 Ingrid Delaet 於 8 月 13 日星期二進行了交易，賣出了公司股票 7143 股。股票平均售價為 150.10 美元，總價值為 1072164.30 美元。交易後，該內部人員持有公司股票 2507 股，價值 376300.70 美元。該交易已在提交給證券交易委員會的法律文件中披露，可通過此鏈接查看。</p>
<p>獲取 <strong>Neurocrine Biosciences</strong> 警報：</p>
<ul>
<li>百時美施貴寶的大舉動：斥資 181 億美元進行 2 筆生物科技交易</li>
</ul>
<p>Ingrid Delaet 最近還進行了以下交易：</p>
<ul>
<li>8 月 6 日星期二，Ingrid Delaet 賣出了 Neurocrine Biosciences 股票 273 股。股票平均售價為 147.70 美元，總價值為 40322.10 美元。</li>
</ul>
<h2>Neurocrine Biosciences 股價表現</h2>
<p>NBIX 週四午盤交易上漲 1.08 美元，報價 147.77 美元。公司股票交易量為 720,170 股，相比平均交易量 819,548 股。該公司的 50 天移動平均價為 141.47 美元，200 天移動平均價為 138.88 美元。該股市值為 148.7 億美元，市盈率為 40.55，β係數為 0.37。Neurocrine Biosciences, Inc.的 52 周最低價為 103.63 美元，52 周最高價為 157.98 美元。</p>
<ul>
<li>在強勁的第三季度報告後，中型市值的 Neurocrine Biosciences 值得買入嗎？</li>
</ul>
<p>Neurocrine Biosciences（納斯達克股票代碼：NBIX）於 8 月 1 日星期四發佈了季度財報。公司報告該季度每股收益為 0.63 美元，低於分析師預期的 1.15 美元（低 0.52 美元）。該季度營收為 5.902 億美元，超過預期的 5.4598 億美元。Neurocrine Biosciences 的淨利潤率為 16.00%，淨資產收益率為 14.86%。公司該季度的營收同比增長 30.4%。在去年同期，公司每股收益為 0.95 美元。賣方分析師預測，Neurocrine Biosciences, Inc.今年將實現每股收益 4.22 美元。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近對該公司的持股進行了調整。RFP Financial Group LLC 在第一季度將其對 Neurocrine Biosciences 的持股增加了 346.5%。RFP Financial Group LLC 現在擁有該公司股票 192 股，價值 26000 美元，上季度購入了額外的 149 股。Mather Group LLC 在第一季度購入了新的 Neurocrine Biosciences 股票，價值 26000 美元。Ashton Thomas Private Wealth LLC 在第二季度購入了新的 Neurocrine Biosciences 股票，價值 28000 美元。Lindbrook Capital LLC 在第四季度將其對 Neurocrine Biosciences 的持股增加了 85.0%。Lindbrook Capital LLC 現在擁有該公司股票 209 股，價值 28000 美元，上季度購入了額外的 96 股。最後，Innealta Capital LLC 在第二季度購入了新的 Neurocrine Biosciences 股票，價值 30000 美元。對沖基金和其他機構投資者擁有該公司股票的 92.59%。</p>
<h2>華爾街分析師觀點</h2>
<p>NBIX 近期成為多家分析師關注的對象。Oppenheimer 將 Neurocrine Biosciences 的目標股價從 216.00 美元上調至 219.00 美元，並在 8 月 2 日星期五的研究報告中給予該股票 “表現優異” 評級。摩根大通將 Neurocrine Biosciences 的股票價格目標從 173.00 美元上調至 181.00 美元，並在 8 月 7 日星期三的研究報告中給予該股票 “超配” 評級。Wedbush 在 5 月 29 日星期三的研究報告中重申了對 Neurocrine Biosciences 的 “表現優異” 評級，並設定了 152.00 美元的股價目標。摩根士丹利將 Neurocrine Biosciences 的股票價格目標從 160.00 美元上調至 170.00 美元，並在 7 月 12 日星期五的研究報告中給予該股票 “超配” 評級。最後，康泰納菲茨重申了對 Neurocrine Biosciences 的 “超配” 評級，並在 7 月 25 日星期四的研究報告中設定了 155.00 美元的股價目標。六位研究分析師對該股票給予持有評級，十六位給予買入評級，兩位給予強烈買入評級。根據 MarketBeat 的數據，Neurocrine Biosciences 目前的共識評級為 “中度買入”，共識目標股價為 158.68 美元。</p>
<p>獲取我們關於 Neurocrine Biosciences 的最新研究報告</p>
<h2>Neurocrine Biosciences 公司簡介</h2>
<p>Neurocrine Biosciences, Inc.是一家在美國和國際市場上為神經、神經內分泌和神經精神疾病研發和銷售藥物的公司。該公司的產品包括用於遲發性運動障礙和與亨廷頓病相關的舞蹈症的 INGREZZA；用於腎上腺功能不全的 ALKINDI；用於經典先天性腎上腺增生的 Efmody 膠囊；用於子宮內膜異位症的 Orilissa 片劑；以及用於治療子宮肌瘤的 Oriahnn 膠囊。</p>
<h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Neurocrine Biosciences</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>邁克爾·伯裏的阿里巴巴賭注及其對整個市場的影響</li>
<li>風險承受能力，一刀切並不適合所有人</li>
<li>傑夫·布朗的 Exegesis AI 股票推薦</li>
<li>在 52 周最低點找到並盈利交易股票</li>
<li>沃倫·巴菲特的賭注：為什麼伯克希爾哈撒韋買入了 Ulta 股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA"/></p>
<p><em>此即時新聞警報由 narrative science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ ⭕ [緊急] 剛剛觸發購買警報（來自市場幕後）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg2"/></p>
<h2>現在是否值得投資神經分泌生物科學（Neurocrine Biosciences）？</h2>
<p>在考慮投資神經分泌生物科學之前，您可能需要聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票... 而神經分泌生物科學並不在這個名單上。</p>
<p>儘管神經分泌生物科學目前在分析師中有一個 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

神經分泌生物科學

<p>英格麗德拉特是神經分泌生物科學公司（NASDAQ: NBIX）的內部人士，於 8 月 13 日出售了 7,143 股，金額約為 2,072,164.30 美元，剩餘 2,507 股價值約 79,300 美元。這筆交易已在提交給美國證券交易委員會（SEC）的文件中披露。此外，NBIX 股票最近經歷了波動，分析師對該股持有不同意見，一些人認為股票具有 “中等買入” 共識，目標價位在 55-65 美元的範圍內</p>

<p>Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Ingrid Delaet sold 7,143 shares of the business's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.10, for a total value of $1,072,164.30. Following the transaction, the insider now owns 2,507 shares of the company's stock, valued at $376,300.70. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link.</p>
<div class="lb-trans"><p>Neurocrine Biosciences, Inc.（納斯達克股票代碼：NBIX）內部人員 Ingrid Delaet 於 8 月 13 日星期二進行了交易，賣出了公司股票 7143 股。股票平均售價為 150.10 美元，總價值為 1072164.30 美元。交易後，該內部人員持有公司股票 2507 股，價值 376300.70 美元。該交易已在提交給證券交易委員會的法律文件中披露，可通過此鏈接查看。</p>
</div><p>Get <strong>Neurocrine Biosciences</strong> alerts:</p>
<ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>Neurocrine Biosciences</strong> 警報：</p>
<ul>
<li>百時美施貴寶的大舉動：斥資 181 億美元進行 2 筆生物科技交易</li>
</ul>
</div><p>Ingrid Delaet also recently made the following trade(s):</p>
<ul>
<li>On Tuesday, August 6th, Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $147.70, for a total value of $40,322.10.</li>
</ul>
<div class="lb-trans"><p>Ingrid Delaet 最近還進行了以下交易：</p>
<ul>
<li>8 月 6 日星期二，Ingrid Delaet 賣出了 Neurocrine Biosciences 股票 273 股。股票平均售價為 147.70 美元，總價值為 40322.10 美元。</li>
</ul>
</div><h2>Neurocrine Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Neurocrine Biosciences 股價表現</h2>
</div><p>NBIX traded up $1.08 during midday trading on Thursday, reaching $147.77. 720,170 shares of the company's stock traded hands, compared to its average volume of 819,548. The firm has a fifty day moving average of $141.47 and a two-hundred day moving average of $138.88. The stock has a market capitalization of $14.87 billion, a price-to-earnings ratio of 40.55 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 52 week low of $103.63 and a 52 week high of $157.98.</p>
<ul>
<li>Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?</li>
</ul>
<div class="lb-trans"><p>NBIX 週四午盤交易上漲 1.08 美元，報價 147.77 美元。公司股票交易量為 720,170 股，相比平均交易量 819,548 股。該公司的 50 天移動平均價為 141.47 美元，200 天移動平均價為 138.88 美元。該股市值為 148.7 億美元，市盈率為 40.55，β係數為 0.37。Neurocrine Biosciences, Inc.的 52 周最低價為 103.63 美元，52 周最高價為 157.98 美元。</p>
<ul>
<li>在強勁的第三季度報告後，中型市值的 Neurocrine Biosciences 值得買入嗎？</li>
</ul>
</div><p>Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts' consensus estimates of $1.15 by ($0.52). The business had revenue of $590.20 million for the quarter, compared to the consensus estimate of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company's revenue for the quarter was up 30.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 EPS. Sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.22 EPS for the current year.</p>
<div class="lb-trans"><p>Neurocrine Biosciences（納斯達克股票代碼：NBIX）於 8 月 1 日星期四發佈了季度財報。公司報告該季度每股收益為 0.63 美元，低於分析師預期的 1.15 美元（低 0.52 美元）。該季度營收為 5.902 億美元，超過預期的 5.4598 億美元。Neurocrine Biosciences 的淨利潤率為 16.00%，淨資產收益率為 14.86%。公司該季度的營收同比增長 30.4%。在去年同期，公司每股收益為 0.95 美元。賣方分析師預測，Neurocrine Biosciences, Inc.今年將實現每股收益 4.22 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. RFP Financial Group LLC grew its stake in shares of Neurocrine Biosciences by 346.5% in the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company's stock worth $26,000 after buying an additional 149 shares during the last quarter. Mather Group LLC. purchased a new stake in Neurocrine Biosciences during the 1st quarter valued at $26,000. Ashton Thomas Private Wealth LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $28,000. Lindbrook Capital LLC boosted its stake in Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company's stock valued at $28,000 after purchasing an additional 96 shares during the last quarter. Finally, Innealta Capital LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $30,000. Hedge funds and other institutional investors own 92.59% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對該公司的持股進行了調整。RFP Financial Group LLC 在第一季度將其對 Neurocrine Biosciences 的持股增加了 346.5%。RFP Financial Group LLC 現在擁有該公司股票 192 股，價值 26000 美元，上季度購入了額外的 149 股。Mather Group LLC 在第一季度購入了新的 Neurocrine Biosciences 股票，價值 26000 美元。Ashton Thomas Private Wealth LLC 在第二季度購入了新的 Neurocrine Biosciences 股票，價值 28000 美元。Lindbrook Capital LLC 在第四季度將其對 Neurocrine Biosciences 的持股增加了 85.0%。Lindbrook Capital LLC 現在擁有該公司股票 209 股，價值 28000 美元，上季度購入了額外的 96 股。最後，Innealta Capital LLC 在第二季度購入了新的 Neurocrine Biosciences 股票，價值 30000 美元。對沖基金和其他機構投資者擁有該公司股票的 92.59%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>NBIX has been the subject of several recent analyst reports. Oppenheimer boosted their target price on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, August 2nd. JPMorgan Chase &amp; Co. lifted their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, August 7th. Wedbush reaffirmed an &#34;outperform&#34; rating and set a $152.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Morgan Stanley lifted their price target on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, July 12th. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, July 25th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $158.68.</p>
<div class="lb-trans"><p>NBIX 近期成為多家分析師關注的對象。Oppenheimer 將 Neurocrine Biosciences 的目標股價從 216.00 美元上調至 219.00 美元，並在 8 月 2 日星期五的研究報告中給予該股票 “表現優異” 評級。摩根大通將 Neurocrine Biosciences 的股票價格目標從 173.00 美元上調至 181.00 美元，並在 8 月 7 日星期三的研究報告中給予該股票 “超配” 評級。Wedbush 在 5 月 29 日星期三的研究報告中重申了對 Neurocrine Biosciences 的 “表現優異” 評級，並設定了 152.00 美元的股價目標。摩根士丹利將 Neurocrine Biosciences 的股票價格目標從 160.00 美元上調至 170.00 美元，並在 7 月 12 日星期五的研究報告中給予該股票 “超配” 評級。最後，康泰納菲茨重申了對 Neurocrine Biosciences 的 “超配” 評級，並在 7 月 25 日星期四的研究報告中設定了 155.00 美元的股價目標。六位研究分析師對該股票給予持有評級，十六位給予買入評級，兩位給予強烈買入評級。根據 MarketBeat 的數據，Neurocrine Biosciences 目前的共識評級為 “中度買入”，共識目標股價為 158.68 美元。</p>
</div><p><strong>Get Our Latest Research Report on Neurocrine Biosciences</strong></p>
<div class="lb-trans"><p>獲取我們關於 Neurocrine Biosciences 的最新研究報告</p>
</div><h2>Neurocrine Biosciences Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Neurocrine Biosciences 公司簡介</h2>
</div><p>Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.</p>
<div class="lb-trans"><p>Neurocrine Biosciences, Inc.是一家在美國和國際市場上為神經、神經內分泌和神經精神疾病研發和銷售藥物的公司。該公司的產品包括用於遲發性運動障礙和與亨廷頓病相關的舞蹈症的 INGREZZA；用於腎上腺功能不全的 ALKINDI；用於經典先天性腎上腺增生的 Efmody 膠囊；用於子宮內膜異位症的 Orilissa 片劑；以及用於治療子宮肌瘤的 Oriahnn 膠囊。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Neurocrine Biosciences</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Michael Burry's Alibaba Bet and the Broader Market Implications</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>Jeff Brown's Exegesis AI Stock Picks</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Neurocrine Biosciences</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>邁克爾·伯裏的阿里巴巴賭注及其對整個市場的影響</li>
<li>風險承受能力，一刀切並不適合所有人</li>
<li>傑夫·布朗的 Exegesis AI 股票推薦</li>
<li>在 52 周最低點找到並盈利交易股票</li>
<li>沃倫·巴菲特的賭注：為什麼伯克希爾哈撒韋買入了 Ulta 股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=NBIX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由 narrative science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ ⭕ [URGENT] Buy Alert just triggered (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ ⭕ [緊急] 剛剛觸發購買警報（來自市場幕後）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9186&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Neurocrine Biosciences right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資神經分泌生物科學（Neurocrine Biosciences）？</h2>
</div><p>Before you consider Neurocrine Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資神經分泌生物科學之前，您可能需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票... 而神經分泌生物科學並不在這個名單上。</p>
</div><p>While Neurocrine Biosciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管神經分泌生物科學目前在分析師中有一個 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

英格麗德·德萊特出售了 7,143 股神經分泌生物科學公司（NASDAQ:NBIX）的股票